Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

By Padmanee Sharma, K. Wagner, J. Wolchok, James P. Allison. Nature Reviews. Cancer, 2011

639 citations recorded by the source corpus.

The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/76e2da35635a487d493d0518f03f8735025bf63d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012, neutral): “All squamous type All doses 13 1 8 (0-36) ND 3 23 (5-54) 43 (15-71)”
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 (2019, background): “The aim of this co-inhibitor is to minimize damage to normal tissues and prevent unwanted autoimmunity [31, 32].”
Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “IFN-α -Stimulates the host’s immune system -Durable responses (from a small subset of melanoma patients) -Low response rates -High-dose toxicity [1]”
Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “The clinical success of anti-CTLA-4 opened a new field termed ‘‘immune checkpoint therapy’’ as additional T cell intrinsic pathways were identified and targeted for clinical development (Sharma et al., 2011; Pardoll, 2012).”
Molecular and genetic properties of tumors associated with local immune cytolytic activity (2015, positive): “With the recent success of checkpoint blockade therapy (against CTLA4 or PD1/PDL1) in inducing durable control of diverse tumors (Hinrichs and Rosenberg, 2014; Sharma et al., 2011), it has become critical to understand why some tumors are not responsive or develop resistance to therapy.”
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (2016, background): “The recent clinical success of checkpoint blockade drugs in treating metastatic melanoma [1] is an exciting development but predictive biomarkers are needed.”
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023, background): “In addition, 4% of patients manifested unconventional immune-related response patterns.(28) The apparent durability of clinical activity in nivolumab-treated patients is remarkable, because this has generally not been observed with chemotherapy or small molecule kinase inhibitors to date but has bee”
Overcoming T cell exhaustion in infection and cancer (2015, background): “Hence, while the presence of immune regulatory molecules including PD-1 and PD-L1 may be a positive prognostic indicator for immunotherapy since these pathways reflect an ongoing immune response [28, 29, 91], the steady state function of TEX and TIL is typically not sufficient to control cancer [14,”
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans (2013, background): “AntiCCR4 mAb therapy can therefore be a unique cancer immunotherapy aiming at depleting eTreg cells without clinically serious adverse effects that would be incurred by total Treg-cell depletion or functional blockade (39).”